Eli Capex To Revenue from 2010 to 2024

LLY Stock  USD 795.35  7.16  0.91%   
Eli Lilly Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.21662403
Current Value
0.23
Quarterly Volatility
0.05737577
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli Lilly's main balance sheet or income statement drivers, such as Depreciation And Amortization of 941.5 M, Interest Expense of 510.2 M or Total Revenue of 35.8 B, as well as many indicators such as Price To Sales Ratio of 16.21, Dividend Yield of 0.0073 or PTB Ratio of 51.34. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
  
Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Eli Lilly and over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Eli Lilly's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Eli Capex To Revenue Regression Statistics

Arithmetic Mean0.1
Geometric Mean0.09
Coefficient Of Variation57.88
Mean Deviation0.04
Median0.08
Standard Deviation0.06
Sample Variance0
Range0.1838
R-Value0.53
Mean Square Error0
R-Squared0.28
Significance0.04
Slope0.01
Total Sum of Squares0.05

Eli Capex To Revenue History

2024 0.23
2023 0.22
2022 0.087
2021 0.0661
2020 0.0827
2019 0.0606
2018 0.14

About Eli Lilly Financial Statements

Eli Lilly investors use historical fundamental indicators, such as Eli Lilly's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.22  0.23 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.